Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Authors
Fizazi, KMassard, C
Bono, P
Jones, R
Kataja, V
James, N
Garcia, J
Protheroe, A
Tammela, T
Elliott, Tony
Mattila, L
Aspegren, J
Vuorela, A
Langmuir, P
Mustonen, M
Affiliation
Institut Gustave Roussy, University of Paris Sud, Villejuif, France.Issue Date
2014-06-25
Metadata
Show full item recordAbstract
ODM-201 is a novel androgen receptor (AR) inhibitor designed to block the growth of prostate cancer cells through high-affinity binding to the AR and inhibition of AR nuclear translocation. This trial assessed ODM-201's safety, pharmacokinetics, and activity in men with metastatic castration-resistant prostate cancer.Citation
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. 2014: Lancet Oncol.Journal
The Lancet OncologyDOI
10.1016/S1470-2045(14)70240-2PubMed ID
24974051Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(14)70240-2